---
schema_version: "secwatch.filing_event.v1"
accession: "0001826667-25-000018"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2025-02-19T23:59:59+00:00"
generated_at: "2026-05-26T12:24:06.907359+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# TriSalus draws $10M under senior secured credit facility; issues warrants for 91,263 shares

## Summary
- Closed Second Tranche of $50M credit facility, receiving $10M on Feb 18, 2025.
- Loan maturity date is April 30, 2029.
- Issued warrants to OrbiMed to purchase 91,263 shares at $5.4787 per share.
- Warrants have a 7-year term and contain customary share/price adjustment provisions.
- Third Tranche of up to $15M remains available until Dec 31, 2025 subject to revenue conditions.

## SEC filing metadata
- accession: 0001826667-25-000018
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2025-02-19T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.03, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000018/0001826667-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000018/tlsi-20250218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001826667-25-000018
- JSON: https://secwatch.observer/filing/0001826667-25-000018.json
- Plain text: https://secwatch.observer/filing/0001826667-25-000018.txt

## Key facts
- Debt Financings
  TriSalus Life Sciences, Inc. incurred term loan of $10 million with OrbiMed Royalty & Credit Opportunities IV, LP maturing April 30, 2029.
  - Instrument: term loan
  - Principal: $10 million
  - Counterparty: OrbiMed Royalty & Credit Opportunities IV, LP
  - Maturity: April 30, 2029
  - Event: incurrence
  source text: y ”) and TriSalus Operating Life Sciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company (the “ Borrower ”) entered into a Credit Agreement (the “ Credit Agreement ”), by and between the Company, as parent, the Borrower, as borrower, OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership (the “ Initial Lender ”), as a lender, each other lender that may from time to time become a party thereto, and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the lenders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000018/0001826667-25-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.